

Servier ranked 1st French pharma across multiple categories in 2023-2024 PatientView U.S. corporate reputation of pharma survey

Suresnes (France), June 27th, 2024 – Servier, independent pharmaceutical company established in the U.S., has risen to the top of the 2023-2024 PatientView ranking results from the survey measuring the reputation of 37 pharmas among 300 U.S. patient organizations asked about their knowledge of the Group. Servier takes first place in twelve out of the fourteen categories considered.

Servier first in twelve categories in the U.S.

Servier ranks first in the PatientView survey conducted among patient organizations declaring to know the company in categories such as patient centricity, information sharing, integrity, services beyond the pill¹, engagement and communication, and overall reputation in the industry.

“Day after day, Servier’s teams endeavor to integrate the patient voice in each of our projects. As a pharmaceutical industry player, our role is to address the challenges faced by patients to provide them with solutions that meet their needs. These results illustrate our capacity to form strong and lasting relationships in our partnerships with the community of patients at each step of their healthcare journey. I would like to thank the patient organizations for the trust they place in us.” **Nicolas Garnier, Chief Patient Officer, Servier.**

Servier in the top 3 of the PatientView global ranking in oncology

On the global scale, Servier maintains its place on the podium following the PatientView survey of the corporate reputation of pharmas working with oncology patient organizations. This result illustrates the Group’s commitment to innovation in this field for patients worldwide. This year, the Group takes first place in the categories of Research & Development, development of services beyond the pill, and data transparency.

“Our unique governance model makes us truly patient-centric. These positive results, particularly in the U.S. where we have been present for only six years, reflect our ongoing commitment to placing patients at the heart of our approach, from the development of medicines to education, awareness and access.” **Arnaud Lallouette, Executive Vice-President Global Medical & Patient Affairs.**

Press contact

presse@servier.com

About Servier

Founded to serve health, Servier is a global pharmaceutical group governed by a Foundation that aspires to have a meaningful social impact, both for patients and for a sustainable world. With its unique governance model, it can fully serve its vocation with a long-term vision: being committed to therapeutic progress to serve patient needs. The 21,900 employees of the Group are committed to this shared vocation, source of inspiration every day.

¹ Any solution that accompanies a treatment, which meets patient needs and leads to better health outcomes

Press release

As a world leader in cardiology, Servier's ambition is to become a focused and innovative player in oncology by targeting rare cancers. That is why the Group allocates over 70% of its R&D budget to developing targeted and innovative therapies in oncology.

Neuroscience and immuno-inflammatory diseases are the future growth drivers. In these areas, Servier is focused on a limited number of diseases in which accurate patient profiling makes it possible to offer a targeted therapeutic response through precision medicine.

To promote access to quality care for all at a lower cost, the Group also offers a range of quality generic drugs covering most pathologies, relying on strong brands in France, Eastern Europe, Brazil and Nigeria. In all these areas, the Group includes the patient voice at each stage of the life cycle of a medicine. Headquartered in France, Servier relies on a strong geographical footprint in over 150 countries and achieved a revenue of €5.3 billion in 2023.

More information on the new Group website: servier.com

Follow us on social media: [LinkedIn](#), [Facebook](#), [Twitter](#), [Instagram](#)

